NCT04530058

The Effects of Metformin on Morbidity and Mortality in Elderly Patients

The Effects of Metformin on Morbidity and Mortality in Elderly Patients- a Prospective Randomized Control Trial (RCT)

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 250 (estimated)
• Sponsor: Hamilton Health Sciences Corporation · Academic / Other
• Sex: All
• Age: 60 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

Elderly patients have an increased susceptibility to burns and a substantial mortality that has not significantly changed over the last three decades. Elderly burn patients not only have an augmented response to burn but also express a prolonged hypermetabolic response.Glucose metabolism with insulin resistance is a hypermetabolic response pathway that profoundly affects post-burn outcomes. The aim if this study is to determine whether metformin can improve morbidity and mortality in elderly burn patients. The investigators hypothesize that metformin will improve clinical outcomes and mortality of elderly burn patients by alleviating the complex inflammatory and hypermetabolic responses after burn.

Conditions

• Burns

Interventions

Type	Name	Description
DRUG	Metformin	Metformin 500 mg twice a day, administered orally or via gastric tube.
DRUG	Placebos	Placebo twice a day, administered orally or via gastric tube.

Timeline

• Start date: 2024-11-01
• Primary completion: 2028-03-01
• Completion: 2029-03-01
• First posted: 2020-08-28
• Last updated: 2024-10-02

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated drug study